Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

T1D-CATCH Protocol: Collaboration Around Technology Using Community Health Workers for Young Adults With Type 1 Diabetes (T1D-CATCH)

20. Oktober 2026 aktualisiert von: Albert Einstein College of Medicine

The objective of this study is to test the early effects and implementation of an enhanced community health worker (CHW) model (T1D-CATCH) that encourages and supports diabetes technology use in young adults from underrepresented minority groups (YA-URMs) with type 1 diabetes (T1D). The investigators will conduct a 9-month randomized controlled trial in which YA-URMs will be randomized to T1D-CATCH or usual care. The investigators will recruit from adult and pediatric endocrinology and primary care practices in a large safety-net health system in the Bronx, New York. Our specific aims are to 1) evaluate T1D-CATCH effects on technology initiation and continued use over 6 months and 2) evaluate T1D-CATCH implementation using Proctor's Taxonomy of Implementation Outcomes: feasibility, adoption, fidelity, and cost.

Studienübersicht

Status

Abgeschlossen

Intervention / Behandlung

Detaillierte Beschreibung

The study will involve a 9-month randomized control trial of usual care versus T1D-CATCH, an intervention that enhances core community health worker (CHW) service roles to support increased use of T1D technology in young adults (underrepresented minorities) (YA-URM's). Participants will be recruited from primary and specialty care practices at Montefiore Medical Center in the Bronx, New York, which is a large safety-net hospital system in one of the poorest counties in the U.S. Two young adult-aged CHWs from the Montefiore CHW program will be trained extensively per our Supporting Emerging Adults with Diabetes (SEAD) program manuals. For YA-URMs, CHWs will conduct hands-on diabetes technology education, goal-setting, peer support, and social service linkage. CHWs will also help shift insurance approval tasks away from busy providers and better align patient-provider priorities through close communication between the YA-URM and provider. Group sessions will be optional and will follow the YA-centric education curriculum developed in Dr. Agarwal's Supporting Emerging Adults with Diabetes (SEAD) program.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

119

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • New York
      • The Bronx, New York, Vereinigte Staaten, 10461
        • Albert Einstein College of Medicine

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 35 Jahre (Erwachsene)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • T1D duration ≥6 months
  • 18-35 years old
  • Self-identified URM status: non-Hispanic Black or Hispanic
  • English- or Spanish-speaking
  • Not currently on a connected diabetes technology system (includes never offered, prescribed but not started within 3 months of receiving the device, discontinued, or previously refused technology)

Exclusion Criteria:

  • Developmental or sensory disability interfering with study participation
  • Current pregnancy
  • Participation in another behavioral or diabetes technology intervention study in the past 6 months.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Versorgungsforschung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Doppelt

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: T1D-CATCH

The CHW intervention will consist of both individual and optional group sessions with YA-URMs with T1D. In individual sessions, CHWs will provide T1D technology education, peer support, and social needs management. Over the 9-month study period, session frequency will involve weekly individual sessions based on participant technology milestones and an optional monthly CHW-led peer group support session. CHW individual and group sessions will be held via videoconferencing or in person, per participant preference and institutional COVID-19 rules.

As defined by the Centers for Disease Control and Prevention (CDC), a CHW is "a frontline public health worker who is a trusted member of a community or who has a thorough understanding of the community being served, and leverages this unique position to link health systems, social services, and communities". CHWs engender trust with patients by having direct community and lived experience, offering specific support and empathy that may be difficult for other diabetes care professionals to provide. In addition, CHWs have firsthand understanding of cultural barriers to traditional western healthcare and can promote patient-centered culturally-relevant care. They enhance team-based care by helping providers with extra outreach, social needs management, time-consuming tasks, and aligning patient-provider priorities.

CHWs in this project will provide social needs assessment and management, introduction to diabetes technologies, and support for onboarding to technology.

Kein Eingriff: Usual Care Control Condition

Control arm participants will receive usual primary or endocrine care at Montefiore. Usual care consists of a physician or nurse practitioner visit with review of blood sugars and treatment decisions based on provider experience. Physicians in endocrinology practices are nested within a diabetes center with access to diabetes nurse practitioners/educators, dieticians, a psychologist, and nurses. In all practices, patients are recommended to see their physician or nurse practitioner every 3 months and attend individual or group sessions.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Technology Initiation
Zeitfenster: Up to 6 months after initiating intervention

Technology initiation will be assessed by the percentage of participants initiating diabetes technology and will be reported as a binary variable (yes/no). Technology will include any combination of continuous glucose monitor (CGM), insulin pump, or CGM and insulin pump. Technology initiation will be defined as at least 1 week of first use during the 6-month period following intervention. Data will be ascertained from electronic medical record (EMR) prescriptions, participant self-reporting, CHW dashboard, and device platform data. Variables will be summarized by study group using summary statistics with counts/percentages.

Up to 6 months after initiating intervention

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Technology Initiation
Zeitfenster: Up to 3 months after initiating intervention

Technology initiation will be assessed by the percentage of participants initiating diabetes technology and will be reported as a binary variable (yes/no). Technology will include any combination of continuous glucose monitor (CGM), insulin pump, or CGM and insulin pump. Technology initiation will be defined as at least 1 week of first use during the 3-month period following intervention. Data will be ascertained from electronic medical record (EMR) prescriptions, participant self-reporting, CHW dashboard, and device platform data. Variables will be summarized by study group using summary statistics with counts/percentages.

Up to 3 months after initiating intervention
Continued Technology Use - Percent Use
Zeitfenster: 9 months following intervention

Continued technology use by study end will be determined from device platform metrics detailing days/percent time used, in addition to self-report. Per standard diabetes technology clinical trial guidelines, CGM use is defined as pump use >90% time. The percentage of time used (% used) will be summarized by study arm using basic descriptive statistics. A target of at least 90% CGM wear-time is associated with the best outcomes for glycemic control.

9 months following intervention
Continued Technology Use - Days of Wear
Zeitfenster: 9 months following intervention

Continued technology use by study end will be determined from device platform metrics detailing days/percent time used, in addition to self-report. Per standard diabetes technology clinical trial guidelines, CGM use is defined as ≥ 5/7 days wear over the 9 month period. Days of wear will be summarized study arm using basic descriptive statistics. A target of at least 5/7 days of CGM wear-time is associated with the best outcomes for glycemic control.

9 months following intervention

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Feasibility Check
Zeitfenster: 6 months (post-intervention)

Post-intervention interviews examining intervention content, complexity, comfort, delivery, and credibility

6 months (post-intervention)
Adoption
Zeitfenster: 9 months (post-intervention)

Measured by recruitment logs

9 months (post-intervention)
Adoption
Zeitfenster: 9 months (post-intervention)

Measured by electronic medical records (EMR)

9 months (post-intervention)
Adoption
Zeitfenster: 9 months (post-intervention)

Measured by young adult participant consent rates

9 months (post-intervention)
Adoption
Zeitfenster: 9 months (post-intervention)

Measured by percentage of provider opt-in

9 months (post-intervention)
Adoption
Zeitfenster: 9 months (post-intervention)

Measured by CHW communications

9 months (post-intervention)
Fidelity
Zeitfenster: Baseline

Measured by the community health worker (CHW) dashboard

Baseline
Fidelity
Zeitfenster: Baseline

Measured by electronic medical records (EMR) to analyze session attendance

Baseline
Fidelity
Zeitfenster: Baseline

Measured by content delivery

Baseline
Fidelity
Zeitfenster: 3 month mark

Measured by community health workers (CHW) dashboard

3 month mark
Fidelity
Zeitfenster: 3 month mark

Measured by CHW session recordings

3 month mark
Fidelity
Zeitfenster: 3 month mark

Measured by EMR to analyze session attendance

3 month mark
Fidelity
Zeitfenster: 3 month mark

Measured by content delivery

3 month mark
Fidelity
Zeitfenster: 3 month mark

Measured by insurance tasks

3 month mark
Fidelity
Zeitfenster: 6 month mark

Measured by CHW dashboard

6 month mark
Fidelity
Zeitfenster: 6 month mark

Measured by CHW session recordings

6 month mark
Fidelity
Zeitfenster: 6 month mark

Measured by EMR to analyze session attendance

6 month mark
Fidelity
Zeitfenster: 6 month mark

Measured by content delivery

6 month mark
Fidelity
Zeitfenster: 6 month mark

Measured by insurance tasks

6 month mark
Cost
Zeitfenster: 6 months (post-intervention)

Measured by time sheets, receipts, and budget to analyze CHW salary/benefits

6 months (post-intervention)
Cost
Zeitfenster: 6 months (post-intervention)

Measured by time sheets, receipts, and budget to analyze CHW equipment

6 months (post-intervention)
Cost
Zeitfenster: 6 months (post-intervention)

Measured by time sheets, receipts, and budget to analyze CHW consumables

6 months (post-intervention)
YA-URM Autonomy/ Competence, Social Support
Zeitfenster: Baseline

Measured using the Healthcare Self-Determination survey

Baseline
YA-URM Autonomy/ Competence, Social Support
Zeitfenster: 3 month mark

Measured using the Healthcare Self-Determination survey

3 month mark
YA-URM Autonomy/ Competence, Social Support
Zeitfenster: 6 month mark

Measured using the Healthcare Self-Determination survey

6 month mark
YA-URM Autonomy/ Competence, Social Support
Zeitfenster: 9 month mark

Measured using the Healthcare Self-Determination survey

9 month mark
Hemoglobin A1c
Zeitfenster: Baseline

Obtained by POC (in clinic) or laboratory (DCA Vantage)

Baseline
Hemoglobin A1c
Zeitfenster: 3 month mark

Obtained by POC (in clinic) or laboratory (DCA Vantage)

3 month mark
Hemoglobin A1c
Zeitfenster: 6 month mark

Obtained by POC (in clinic) or laboratory (DCA Vantage)

6 month mark
Hemoglobin A1c
Zeitfenster: 9 month mark

Obtained by POC (in clinic) or laboratory (DCA Vantage)

9 month mark
Quality of Life (Diabetes Distress)
Zeitfenster: Baseline

Validated survey: Type 1 Diabetes and Life Scale - Young Adult (T1DAL-YA)

Likert Scale: 1-5 (1= no, not at all true, 2=no, not very true, 3=sometimes true, sometimes not true, 4=yes, a little true, 5= yes, very true)

Baseline
Quality of Life (Diabetes Distress)
Zeitfenster: Baseline

Validated surveys: Problem Areas in Diabetes (PAID)

The scores for each item are summed, then multiplied by 1.25 to generate a total score out of 100.

  • Total scores of 40 and above: severe diabetes distress
  • Individual items scored 3 or 4: moderate to severe distress to be discussed during the appointment following completion of the questionnaire.
Baseline
Quality of Life (Diabetes Distress)
Zeitfenster: Baseline

Validated survey: Diabetes Self-Management Questionnaire (DSMQ)

Baseline
Quality of Life (Diabetes Distress)
Zeitfenster: Baseline

Validated survey: Healthcare Climate Questionnaire (HCCQ)

Likert Scale (1-7) 1= strongly disagree ---- 7= strongly agree

Higher average scores represent a higher level of perceived autonomy support.

Baseline
Quality of Life (Diabetes Distress)
Zeitfenster: 3 month follow-up

Validated survey: Type 1 Diabetes and Life Scale - Young Adult (T1DAL-YA)

Likert Scale: 1-5 (1= no, not at all true, 2=no, not very true, 3=sometimes true, sometimes not true, 4=yes, a little true, 5= yes, very true)

3 month follow-up
Quality of Life (Diabetes Distress)
Zeitfenster: 3 month follow-up

Validated surveys: Problem Areas in Diabetes (PAID)

The scores for each item are summed, then multiplied by 1.25 to generate a total score out of 100.

  • Total scores of 40 and above: severe diabetes distress
  • Individual items scored 3 or 4: moderate to severe distress to be discussed during the appointment following completion of the questionnaire.
3 month follow-up
Quality of Life (Diabetes Distress)
Zeitfenster: 3 month follow-up

Validated survey: Diabetes Self-Management Questionnaire (DSMQ)

3 month follow-up
Quality of Life (Diabetes Distress)
Zeitfenster: 3 month follow-up

Validated survey: Healthcare Climate Questionnaire (HCCQ)

Likert Scale (1-7) 1= strongly disagree ---- 7= strongly agree

Higher average scores represent a higher level of perceived autonomy support.

3 month follow-up
Quality of Life (Diabetes Distress
Zeitfenster: 6 month follow-up

Validated survey: Type 1 Diabetes and Life Scale - Young Adult (T1DAL-YA)

Likert Scale: 1-5 (1= no, not at all true, 2=no, not very true, 3=sometimes true, sometimes not true, 4=yes, a little true, 5= yes, very true)

6 month follow-up
Quality of Life (Diabetes Distress)
Zeitfenster: 6 month follow-up

Validated surveys: Problem Areas in Diabetes (PAID)

The scores for each item are summed, then multiplied by 1.25 to generate a total score out of 100.

  • Total scores of 40 and above: severe diabetes distress
  • Individual items scored 3 or 4: moderate to severe distress to be discussed during the appointment following completion of the questionnaire.
6 month follow-up
Quality of Life (Diabetes Distress)
Zeitfenster: 6 month follow-up

Validated survey: Diabetes Self-Management Questionnaire (DSMQ)

6 month follow-up
Quality of Life (Diabetes Distress)
Zeitfenster: 6 month follow-up

Validated survey: Healthcare Climate Questionnaire (HCCQ)

Likert Scale (1-7) 1= strongly disagree ---- 7= strongly agree

Higher average scores represent a higher level of perceived autonomy support.

6 month follow-up

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Shivani Agarwal, MD, MPH, Albert Einstein College of Medicine

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

7. November 2022

Primärer Abschluss (Tatsächlich)

8. September 2025

Studienabschluss (Tatsächlich)

8. Dezember 2025

Studienanmeldedaten

Zuerst eingereicht

16. Dezember 2021

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

26. Januar 2022

Zuerst gepostet (Tatsächlich)

27. Januar 2022

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

12. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

20. Oktober 2026

Zuletzt verifiziert

1. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren